Войти в систему

Home
    - Создать дневник
    - Написать в дневник
       - Подробный режим

LJ.Rossia.org
    - Новости сайта
    - Общие настройки
    - Sitemap
    - Оплата
    - ljr-fif

Редактировать...
    - Настройки
    - Список друзей
    - Дневник
    - Картинки
    - Пароль
    - Вид дневника

Сообщества

Настроить S2

Помощь
    - Забыли пароль?
    - FAQ
    - Тех. поддержка



Пишет bioRxiv Subject Collection: Neuroscience ([info]syn_bx_neuro)
@ 2024-09-02 07:52:00


Previous Entry  Add to memories!  Tell a Friend!  Next Entry
Astrocyte-derived MFG-E8 facilitates microglial synapse elimination in Alzheimer's disease mouse models
Region-specific synapse loss is an early pathological hallmark in Alzheimer's disease (AD). Emerging data in mice and humans highlight microglia, the brain-resident macrophages, as cellular mediators of synapse loss; however, the upstream modulators of microglia-synapse engulfment remain elusive. Here, we report a distinct subset of astrocytes, which are glial cells essential for maintaining synapse homeostasis, appearing in a region-specific manner with age and amyloidosis at onset of synapse loss. These astrocytes are distinguished by their peri-synaptic processes which are 'bulbous' in morphology, contain accumulated p62-immunoreactive bodies, and have reduced territorial domains, resulting in a decrease of astrocyte-synapse coverage. Using integrated in vitro and in vivo approaches, we show that astrocytes upregulate and secrete phagocytic modulator, milk fat globule-EGF factor 8 (MFG-E8), which is sufficient and necessary for promoting microglia-synapse engulfment in their local milieu. Finally, we show that knocking down Mfge8 specifically from astrocytes using a viral CRISPR-saCas9 system prevents microglia-synapse engulfment and ameliorates synapse loss in two independent amyloidosis mouse models of AD. Altogether, our findings highlight astrocyte-microglia crosstalk in determining synapse fate in amyloid models and nominate astrocytic MFGE8 as a potential target to ameliorate synapse loss during the earliest stages of AD.


(Читать комментарии) (Добавить комментарий)